TNFSF13B and lymphopenia: It is known that myeloablative treatment before HCT induces a lymphopenia condition in which the B cell compartment reconstitutes in a setting of a high B-cell activating factor (BAFF)-to-B cell ratio and altered B cell homeostasis (61, 62).